Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX)

41 filings reported holding RNTX - Rein Therapeutics, Inc. - Common Stock, $0.001 par value as of Q3 2025.
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 8.49M shares of 23.6M outstanding shares and own 35.97% of the company stock.
Largest 10 shareholders include Voss Capital, LP (2.67M shares), BIOS Capital Management, LP (1.69M shares), VANGUARD GROUP INC (1.17M shares), Prosight Management, LP (568K shares), UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO (512K shares), Cable Car Capital, LP (420K shares), Sigma Planning Corp (254K shares), GEODE CAPITAL MANAGEMENT, LLC (247K shares), Senvest Management, LLC (231K shares), and GAGNON SECURITIES LLC (229K shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.